A. MERT Et Al. , "Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls," Rheumatology International , vol.42, no.3, pp.457-467, 2022
MERT, A. Et Al. 2022. Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls. Rheumatology International , vol.42, no.3 , 457-467.
MERT, A., VAHABOĞLU, H., Arslan, F., Batirel, A., Saraçoğlu, K. T., Bastug, A., ... Çağatay, A.(2022). Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls. Rheumatology International , vol.42, no.3, 457-467.
MERT, Ali Et Al. "Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls," Rheumatology International , vol.42, no.3, 457-467, 2022
MERT, Ali Et Al. "Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls." Rheumatology International , vol.42, no.3, pp.457-467, 2022
MERT, A. Et Al. (2022) . "Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls." Rheumatology International , vol.42, no.3, pp.457-467.
@article{article, author={Ali MERT Et Al. }, title={Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls}, journal={Rheumatology International}, year=2022, pages={457-467} }